Australia markets closed

TheraVet SA (ALVET.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
5.24-0.02 (-0.38%)
At close: 05:25PM CET
Full screen
Previous close5.26
Open5.26
BidN/A x N/A
AskN/A x N/A
Day's range5.22 - 5.36
52-week range5.22 - 8.56
Volume1,445
Avg. volume2,198
Market cap16.893M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est11.00
  • Business Wire

    TheraVet Strengthens Its Sales Organisation in France by Signing an Important Distribution Agreement for BIOCERA-VET®

    GOSSELIES, Belgium, January 18, 2022--Regulatory News: TheraVet (Paris:ALVET) (Brussels:ALVET) (ISIN: BE0974387194 - ticker: ALVET), a biotech company developing pioneering treatments for osteoarticular disease in pets, announced today the signature of a non-exclusive commercial distribution agreement for its BIOCERA-VET® bone substitute in France with the veterinary co-operative Centravet, one of France’s leading wholesaler/distributors of animal health products. The agreement covers the BIOCER

  • Business Wire

    TheraVet Announces the Initiation of Coverage of Its Stock by Degroof Petercam

    GOSSELIES, Belgique, January 10, 2022--Regulatory News: TheraVet (code ISIN: BE0974387194 - mnémonique: ALVET) (Paris:ALVET) (Brussels:ALVET), a pioneering company in the management of osteoarticular diseases in companion animals, announces today the initiation of commissioned research coverage of its title by Degroof Petercam, with a study entitled "Revolutionizing the treatment of osteoarticular diseases".

  • Business Wire

    TheraVet Is Strengthening Its Corporate Governance With the Appointment of Three New Independent Board Members

    GOSSELIES, Wallonia, Belgium, December 16, 2021--Regulatory News: TheraVet (ISIN: BE0974387194 - ticker: ALVET), a biotechnology company specialising in osteoarticular treatments for animals, is strengthening its corporate governance by co-opting two new independent directors (Simon Wheeler and Nesya Goris) and an independent observer (Christian Schirvel). Their appointment to the board is subject to approval by shareholders in the Company’s next Shareholders’ General Meeting. Simon Wheeler will